These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
970 related items for PubMed ID: 19843632
21. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Lu M, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VC, Cryns VL. Clin Cancer Res; 2008 May 15; 14(10):3168-76. PubMed ID: 18483385 [Abstract] [Full Text] [Related]
22. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression. Lee J, Hwangbo C, Lee JJ, Seo J, Lee JH. Oncol Rep; 2010 Jan 15; 23(1):229-37. PubMed ID: 19956887 [Abstract] [Full Text] [Related]
23. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K, Douglas L, Delaney A, Houghton JA. Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455 [Abstract] [Full Text] [Related]
24. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Zhang L, Fang B. Cancer Gene Ther; 2005 Mar 01; 12(3):228-37. PubMed ID: 15550937 [Abstract] [Full Text] [Related]
25. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Cancer Res; 2000 Aug 01; 60(15):4122-9. PubMed ID: 10945619 [Abstract] [Full Text] [Related]
26. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M. Oncogene; 2006 Dec 07; 25(58):7618-34. PubMed ID: 16983347 [Abstract] [Full Text] [Related]
27. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Mori T, Doi R, Toyoda E, Koizumi M, Ito D, Kami K, Kida A, Masui T, Kawaguchi Y, Fujimoto K. Surgery; 2005 Jul 07; 138(1):71-7. PubMed ID: 16003319 [Abstract] [Full Text] [Related]
28. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Cancer Res; 1999 Feb 01; 59(3):734-41. PubMed ID: 9973225 [Abstract] [Full Text] [Related]
29. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Earel JK, VanOosten RL, Griffith TS. Cancer Res; 2006 Jan 01; 66(1):499-507. PubMed ID: 16397266 [Abstract] [Full Text] [Related]
30. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. Aroui S, Brahim S, Hamelin J, De Waard M, Bréard J, Kenani A. Apoptosis; 2009 Nov 01; 14(11):1352-65. PubMed ID: 19731037 [Abstract] [Full Text] [Related]
31. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Zhang X, Li W, Olumi AF. Clin Cancer Res; 2007 Dec 01; 13(23):7181-90. PubMed ID: 18056199 [Abstract] [Full Text] [Related]
32. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Kazhdan I, Marciniak RA. Cancer Gene Ther; 2004 Oct 01; 11(10):691-8. PubMed ID: 15354201 [Abstract] [Full Text] [Related]
33. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand. Yasuda T, Yoshida T, Goda AE, Horinaka M, Yano K, Shiraishi T, Wakada M, Mizutani Y, Miki T, Sakai T. Mol Cancer Res; 2008 Dec 01; 6(12):1852-60. PubMed ID: 19074830 [Abstract] [Full Text] [Related]
34. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. Li Y, Wang H, Wang Z, Makhija S, Buchsbaum D, LoBuglio A, Kimberly R, Zhou T. Cancer Res; 2006 Sep 01; 66(17):8520-8. PubMed ID: 16951164 [Abstract] [Full Text] [Related]
35. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation. Kim JY, Kim EH, Park SS, Lim JH, Kwon TK, Choi KS. J Cell Biochem; 2008 Dec 15; 105(6):1386-98. PubMed ID: 18980244 [Abstract] [Full Text] [Related]
36. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L). Guseva NV, Rokhlin OW, Taghiyev AF, Cohen MB. Breast Cancer Res Treat; 2008 Feb 15; 107(3):349-57. PubMed ID: 17453339 [Abstract] [Full Text] [Related]
37. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC, Sandler AD. Cancer Res; 2002 Jun 01; 62(11):3093-9. PubMed ID: 12036919 [Abstract] [Full Text] [Related]
38. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Kurbanov BM, Fecker LF, Geilen CC, Sterry W, Eberle J. Oncogene; 2007 May 17; 26(23):3364-77. PubMed ID: 17160022 [Abstract] [Full Text] [Related]
39. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J. J Orthop Res; 2003 Sep 17; 21(5):949-57. PubMed ID: 12919886 [Abstract] [Full Text] [Related]
40. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. Abdollahi T, Robertson NM, Abdollahi A, Litwack G. Cancer Res; 2003 Aug 01; 63(15):4521-6. PubMed ID: 12907626 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]